Obstructive sleep apnea and longitudinal Alzheimer’s disease biomarker changes
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Study Objectives: To determine the effect of self-reported clinical diagnosis of obstructive sleep apnea (OSA) on longitudinal changes in brain amyloid PET and CSF biomarkers (Aβ42, T-tau, and P-tau) in cognitively normal (NL), mild cognitive impairment (MCI), and Alzheimer’s disease (AD) elderly. Methods: Longitudinal study with mean follow-up time of 2.52 ± 0.51 years. Data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. Participants included 516 NL, 798 MCI, and 325 AD elderly. Main outcomes were annual rate of change in brain amyloid burden (i.e. longitudinal increases in florbetapir PET uptake or decreases in CSF Aβ42 levels); and tau protein aggregation (i.e. longitudinal increases in CSF total tau [T-tau] and phosphorylated tau [P-tau]). Adjusted multilevel mixed effects linear regression models with randomly varying intercepts and slopes was used to test whether the rate of biomarker change differed between participants with and without OSA. Results: In NL and MCI groups, OSA+ subjects experienced faster annual increase in florbetapir uptake (B = .06, 95% CI = .02, .11 and B = .08, 95% CI = .05, .12, respectively) and decrease in CSF Aβ42 levels (B = −2.71, 95% CI = −3.11, −2.35 and B = −2.62, 95% CI = −3.23, −2.03, respectively); as well as increases in CSF T-tau (B = 3.68, 95% CI = 3.31, 4.07 and B = 2.21, 95% CI = 1.58, 2.86, respectively) and P-tau (B = 1.221, 95% CI = 1.02, 1.42 and B = 1.74, 95% CI = 1.22, 2.27, respectively); compared with OSA− participants. No significant variations in the biomarker changes over time were seen in the AD group. Conclusions: In both NL and MCI, elderly, clinical interventions aimed to treat OSA are needed to test if OSA treatment may affect the progression of cognitive impairment due to AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Occurrence of Sleep-Disordered Breathing among Middle-Aged Adults
Young, T., Palta, M., Dempsey, J., Skatrud, J., Weber, S., & Badr, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304293281704 · Cited by 10,183 · cited 1×
“001 . presence of AHI4% ≥5/h and daytime symptoms across all ages [57].”
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 1×
“Our findings in a cohort of self-reported OSA patients suggest that untreated OSA can predispose to neurodegenerative processes in the long-term by gradually weakening brain structure and altering its functioning [49, 50].”
Self-citationSleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572 · cited 1×
“ADNI criteria for subject classification are described elsewhere [12].”
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationBrain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590 · cited 1×
“Second, particularly in those with MCI, is the presence of increased vascular risk in this group (i.e. higher rates of diabetes and obesity) (Table 1), as onset of cognitive impairment is likely to occur at a lower severity of Alzheimer lesions in individuals with more vascular pathology [41].”
Hernan, M. A. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.2.176 · Cited by 1,445
Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.028 · Cited by 1,265
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Brain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875 · cited 1×
“Our study possesses several strengths including a well-defined cohort, and objective assessment of amyloid burden and CSF P-tau/T-tau, which allowed for a high degree of certainty regarding measurement of clinical groups and outcomes [54].”
Cited by
Bubu, O. M., Andrade, A. G., Umasabor-Bubu, O. Q., Hogan, M. M., Turner, A. D., de Leon, M. J., Ogedegbe, G., Ayappa, I., Jean-Louis G, G., Jackson, M. L., et al. (2020) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2019.101250 · Cited by 389
Self-citationSleep apnea and the risk of dementia: a systematic review and meta-analysis
Guay‐Gagnon, M., Vat, S., Forget, M., Tremblay‐Gravel, M., Ducharme, S., Nguyen, Q. D., & Desmarais, P. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13589 · Cited by 107
“…longitudinal study found that in cognitively normal and mild cognitive impairment patients, the presence of sleep apnea was associated with a faster decrease in CSF amyloid ß42, as well as a faster increase in CSF T-tau and P-tau compared with patients without sleep apnea (Bubu et al., 2019).”
ResultVan Egroo, M., van Someren, E. J. W., Grinberg, L. T., Bennett, D. A., & Jacobs, H. I. L. (2024) · Annals of Neurology · doi:10.1002/ana.26880 · Cited by 28
“In particular, sleep apnea has been linked to increased accumulation and/or reduced clearance of A β and tau proteins, 52,53 as well as earlier onset of AD cognitive symptoms.”
Background
Metadata
- Authors
- Bubu, O. M., Pirraglia, E., Andrade, A. G., Sharma, R. A., Gimenez-Badia, S., Umasabor-Bubu, O. Q., Hogan, M. M., Shim, A. M., Mukhtar, F., Sharma, N., Mbah, A. K., Seixas, A. A., Kam, K., Zizi, F., Borenstein, A. R., Mortimer, J. A., Kip, K. E., Morgan, D., Rosenzweig, I., Ayappa, I., Rapoport, D. M., Jean-Louis, G., Varga, A. W., & Osorio, R. S.
- Venue
- Sleep
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-02-22
- Volume
- 42
- Issue
- 6
- ISSN
- 0161-8105 (ISSN-L)
- 1550-9109
- OpenAlex
- W2915905384
- Cited by
- 164
- References
- 23
- FWCI
- 10.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Obstructive sleep apnea and longitudinal Alzheimer’s disease biomarker changes. https://app.cochat.ai/papers/10.1093/sleep/zsz048
- The paper
- Bubu, O. M., Pirraglia, E., Andrade, A. G., Sharma, R. A., Gimenez-Badia, S., Umasabor-Bubu, O. Q., Hogan, M. M., Shim, A. M., Mukhtar, F., Sharma, N., Mbah, A. K., Seixas, A. A., Kam, K., Zizi, F., Borenstein, A. R., Mortimer, J. A., Kip, K. E., Morgan, D., Rosenzweig, I., . . . Osorio, R. S. (2019). Obstructive sleep apnea and longitudinal Alzheimer’s disease biomarker changes. Sleep. https://doi.org/10.1093/sleep/zsz048
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.